European regulators have expanded the use of Bayer and Regeneron’s Eylea (aflibercept), approving the drug’s use to treat visual impairment due to macular oedema secondary to Retinal Vein Occlusion.
The indication now includes macular oedema following Branch Retinal Vein Occlusion (BRVO), adding to the previously approved macular oedema secondary to Central Retinal Vein Occlusion (CRVO).
RVO is the second most common retinal vascular disease, affecting an estimated 16.4 million people worldwide. Around 13.9 million patients have the BRVO form, where blood vessels branching from the main vein draining the retina are blocked, leading to retinal oedema.
Bayer Healthcare and Regeneron are working together to develop Eylea, the latter holding exclusive rights in the US and Bayer in the rest of the world.
